



ASX Limited
Market Announcements Office

Phosphagenics' TPM[®]/Oxycodone PHN Trial Completes Enrolment and Dosing

- **Recruitment and dosing of all patient in Phase 2a study of the TPM[®]/Oxycodone topical patch in PHN is complete**
- **Headline results expected in early 1st Qtr 2016**

17 December 2015, Melbourne: Australian biotechnology company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce that recruitment into the topical TPM[®]/Oxycodone Study (POH035-13) is complete and the final patient in the study has completed dosing. The study is a randomised, double blind, placebo controlled Phase 2a study assessing the efficacy and safety of Phosphagenics' TPM[®]/Oxycodone topical patch in 28 postherpetic neuralgia (PHN) patients.

Dr Paul Gavin, Phosphagenics' Chief Scientific Officer, said "This is an important milestone for the TPM[®]/Oxycodone patch. If approved the TPM[®]/Oxycodone patch will be the world's first topical opioid patch for the treatment of localised pain and we believe it can provide significant advantages over current methods of opioid administration. Success in this trial is a key step towards partnering and international regulatory filings."

Phosphagenics' CEO and Managing Director, Dr Ross Murdoch, added, "Pain conditions like postherpetic neuralgia represent a large and undertreated patient population and a significant market opportunity. I see this trial providing us and potential partners with key information, important for not only assessing the utility of the TPM[®]/Oxycodone patch in the treatment of PHN but also for assessing the potential of this patch in other valuable indications."

Headline results from Study POH035-13 are expected in early 2016 with the full analytical report, including the analysis of blood samples, to follow in 2nd quarter 2016.

Enquiries

Dr Ross Murdoch
Phosphagenics Limited
+61 3 9565 1119

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

About Phosphagenics

Phosphagenics Limited is focused on developing and commercialising innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM[®] (Targeted Penetration Matrix). TPM[®] is derived from Vitamin E using a unique, proprietary and patented process and has been proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Amongst its major projects, Phosphagenics' is developing a TPM[®] enhanced oxycodone patch for the treatment of pain associated with Postherpetic neuralgia (presently completing Phase 2a) and is also developing TPM[®] to enhance the feed efficiency and health of livestock.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

Inherent Risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

Forward-looking Statements

Certain statements in this announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.

www.phosphagenics.com